These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25726673)

  • 1. [Recombinant α-2 interferon in preventing the progression of melanoma].
    Korovin SI; Kukushkina MN; Palivets AIu; Fil'chakov FV; Shumilina ES; Ostafĭchuk VV
    Lik Sprava; 2013 Dec; (8):21-30. PubMed ID: 25726673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant interferon: extended follow-up times needed?
    Thoren FB; Strannegård Ö
    Lancet Oncol; 2011 May; 12(5):419. PubMed ID: 21536217
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma.
    Wang R; Jing G; Lv J; Song H; Li C; Wang X; Xia W; Wu Y; Ren G; Guo W
    Genet Mol Res; 2015 Oct; 14(4):11944-54. PubMed ID: 26505342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant interferon therapy for malignant melanoma: the debate.
    Zhou Q; Zhang XS
    Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
    Lens M
    Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy of melanoma: what's new?
    Ascierto PA; Palmieri G; Daponte A; Melucci MT; Satriano RA; Mozzillo N; Castello G;
    Melanoma Res; 2002 Jun; 12(3):293-6. PubMed ID: 12140388
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma.
    Puente Vázquez J; González Larriba JL
    Clin Transl Oncol; 2007 Mar; 9(3):125-6. PubMed ID: 17403622
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon for melanoma.
    Richtig E; Langmann G
    Ophthalmology; 2010 Sep; 117(9):1861. PubMed ID: 20816255
    [No Abstract]   [Full Text] [Related]  

  • 12. How does interferon work? Does it even matter?
    Sondak VK
    Cancer; 2002 Sep; 95(5):947-9. PubMed ID: 12209676
    [No Abstract]   [Full Text] [Related]  

  • 13. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
    Agarwala SS; Gray RJ; Wong MK
    J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon-induced obsessive-compulsive symptoms in malignant melanoma.
    Mavrogiorgou P; Juckel G
    Pharmacopsychiatry; 2012 Jan; 45(1):28-30. PubMed ID: 21989604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alph-2b (Sylatron) for melanoma.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
    [No Abstract]   [Full Text] [Related]  

  • 16. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
    J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon as adjuvant treatment for melanoma.
    Wheatley K; Ives N; Hancock B; Gore M
    Lancet; 2002 Sep; 360(9336):878. PubMed ID: 12243953
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.